Small-molecule protein kinase inhibitors and their effects on the immune system: Implications for cancer treatment

Immunotherapy

Volumn 3, Issue 2, 2011, Pages 213-227

  Ott, Patrick A ^a   Adams, Sylvia ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

cancer; immunotherapy; MAPK; PI3K AKT mTOR; VEGF VEGFR tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

CANCER THERAPY; CARCINOGENESIS; DENDRITIC CELL; DOWN REGULATION; HUMAN; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNE SYSTEM; NEOPLASMS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 79951754050     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.99     Document Type: Review

References (120)

1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escap (Pubitemid 35363648)
2. Zou W: Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5(4), 263-274 (2005). (Pubitemid 40488632)
3. Lurquin C, Lethe B, De Plaen E et al.: Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a mage tumor antigen. J. Exp. Med. 201(2), 249-257 (2005). (Pubitemid 40189434)
4. Peterson AC, Harlin H, Gajewski TF: Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J. Clin. Oncol. 21(12), 2342-2348 (2003). (Pubitemid 46628465)
5. Rosenberg SA, Sherry RM, Morton KE et al.: Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J. Immunol. 175(9), 6169-6176 (2005). (Pubitemid 41508105)
6. Yuan J, Gnjatic S, Li H et al.: CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T-cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl Acad. Sci. USA 105(51), 20410-20415 (2008).
7. Atkins MB, Lotze MT, Dutcher JP et al.: High-dose recombinant IL-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17(7), 2105-2116 (1999). (Pubitemid 29318842)
8. Hodi FS, ODay SJ, McDermott DF et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
9. De Souza AP, Bonorino C: Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. Expert Rev. Anticancer Ther. 9(9), 1317-1332 (2009).
10. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P: The polarization of immune cells in the tumour environment by TGFb. Nat. Rev. Immunol. 10, 554-567 (2010).
11. Burdelya L, Kujawski M, Niu G et al.: STAT3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J. Immunol. 174(7), 3925-3931 (2005). (Pubitemid 40395966)
12. Nefedova Y, Cheng P, Gilkes D et al.: Activation of dendritic cells via inhibition of JAK2/STAT3 signaling. J. Immunol. 175(7), 4338-4346 (2005). (Pubitemid 41361968)
13. Nefedova Y, Huang M, Kusmartsev S et al.: Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 172(1), 464-474 (2004). (Pubitemid 38020502)
14. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y: The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 203(7), 1651-1656 (2006). (Pubitemid 44036269)
15. Alvarez RH, Valero V, Hortobagyi GN: Emerging targeted therapies for breast cancer. J. Clin. Oncol. 28(20), 3366-3379 (2010).
16. Fecher LA, Amaravadi RK, Schuchter LM, Flaherty KT: Drug targeting of oncogenic pathways in melanoma. Hematol. Oncol. Clin. North Am. 23(3), 599-618 (2009).
17. Calne RY, Collier DS, Lim S et al.: Rapamycin for immunosuppression in organ allografting. Lancet 2(8656), 227 (1989).
18. Neuhaus P, Klupp J, Langrehr JM: mTOR inhibitors: an overview. Liver Transpl. 7(6), 473-484 (2001). (Pubitemid 32547260)
19. Powell JD, Lerner CG, Schwartz RH: Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J. Immunol. 162(5), 2775-2784 (1999). (Pubitemid 29309302)
20. Vanasek TL, Khoruts A, Zell T, Mueller DL: Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: enhanced cell cycle progression promotes recall antigen responsiveness. J. Immunol. 167(10), 5636-5644 (2001). (Pubitemid 33062753)
21. Zheng Y, Collins SL, Lutz MA et al.: A role for mammalian target of rapamycin in regulating T-cell activation versus anergy. J. Immunol. 178(4), 2163-2170 (2007). (Pubitemid 46233414)
22. Delgoffe GM, Kole TP, Zheng Y et al.: The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30(6), 832-844 (2009).
23. Kang J, Huddleston SJ, Fraser JM, Khoruts A: De novo induction of antigen-specific CD4+CD25+foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR. J. Leukoc. Biol. 83(5), 1230-1239 (2008). (Pubitemid 351960355)
24. Battaglia M, Stabilini A, Roncarolo MG: Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105(12), 4743-4748 (2005).
25. Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A: Selective survival of naturally occurring human CD4+CD25+FoxP3+ regulatory T cells cultured with rapamycin. J. Immunol. 178(1), 320-329 (2007). (Pubitemid 46033615)
26. Thomson AW, Turnquist HR, Raimondi G: Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 9(5), 324-337 (2009).
27. Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW: Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific FoxP3+ T regulatory cells and promote organ transplant tolerance. J. Immunol. 178(11), 7018-7031 (2007). (Pubitemid 46847428)
28. Hackstein H, Taner T, Logar AJ, Thomson AW: Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 100(3), 1084-1087 (2002). (Pubitemid 34832646)
29. Hackstein H, Taner T, Zahorchak AF et al.: Rapamycin inhibits IL-4 induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 101(11), 4457-4463 (2003). (Pubitemid 36857814)
30. Monti P, Mercalli A, Leone BE, Valerio DC, Allavena P, Piemonti L: Rapamycin impairs antigen uptake of human dendritic cells. Transplantation 75(1), 137-145 (2003). (Pubitemid 36139710)
31. Gulen MF, Kang Z, Bulek K et al.: The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity 32(1), 54-66 (2010).
32. Donahue AC, Fruman DA: Distinct signaling mechanisms activate the target of rapamycin in response to different B-cell stimuli. Eur. J. Immunol. 37(10), 2923-2936 (2007). (Pubitemid 47578311)
33. Heidt S, Roelen DL, Eijsink C, Van Kooten C, Claas FH, Mulder A: Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. Transplantation 86(9), 1292-1300 (2008).
34. Wai LE, Fujiki M, Takeda S, Martinez OM, Krams SM: Rapamycin, but not cyclosporine or fk506, alters natural killer cell function. Transplantation 85(1), 145-149 (2008).
35. De Paulis A, Cirillo R, Ciccarelli A, De Crescenzo G, Oriente A, Marone G: Characterization of the anti-inflammatory effect of FK-506 on human mast cells. J. Immunol. 147(12), 4278-4285 (1991).
36. Ohtani M, Nagai S, Kondo S et al.: Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced IL-12 production in dendritic cells. Blood 112(3), 635-643 (2008).
37. Weichhart T, Costantino G, Poglitsch M et al.: The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 29(4), 565-577 (2008).
38. Rao RR, Li Q, Odunsi K, Shrikant PA: The mTOR kinase determines effector versus memory CD8+ T-cell fate by regulating the expression of transcription factors T-bet and eomesodermin. Immunity 32(1), 67-78 (2010).
39. Guiducci C, Ghirelli C, Marloie-Provost MA et al.: PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. J. Exp. Med. 205(2), 315-322 (2008). (Pubitemid 351281597)
40. Aksoy E, Vanden Berghe W, Detienne S et al.: Inhibition of phosphoinositide 3-kinase enhances TRIF-dependent NF-kB activation and IFN-b synthesis downstream of Toll-like receptor 3 and 4. Eur. J. Immunol. 35(7), 2200-2209 (2005). (Pubitemid 41015059)
41. Fukao T, Tanabe M, Terauchi Y et al.: PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat. Immunol. 3(9), 875-881 (2002).
42. Guha M, Mackman N: The phosphatidylinositol 3-kinase-AKT pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J. Biol. Chem. 277(35), 32124-32132 (2002). (Pubitemid 34969025)
43. Williams DL, Li C, Ha T et al.: Modulation of the phosphoinositide 3-kinase pathway alters innate resistance to polymicrobial sepsis. J. Immunol. 172(1), 449-456 (2004). (Pubitemid 38020500)
44. Polumuri SK, Toshchakov VY, Vogel SN: Role of phosphatidylinositol-3 kinase in transcriptional regulation of TLR-induced IL-12 and IL-10 by Fc g receptor ligation in murine macrophages. J. Immunol. 179(1), 236-246 (2007). (Pubitemid 46986539)
45. Arrighi JF, Rebsamen M, Rousset F, Kindler V, Hauser C: A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-a, and contact sensitizers. J. Immunol. 166(6), 3837-3845 (2001). (Pubitemid 32224909)
46. Lu HT, Yang DD, Wysk M et al.: Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (MKK3)-deficient mice. EMBO J. 18(7), 1845-1857 (1999). (Pubitemid 29158528)
47. Yoshimura S, Bondeson J, Foxwell BM, Brennan FM, Feldmann M: Effective antigen presentation by dendritic cells is NF-kB dependent: coordinate regulation of MHC, costimulatory molecules and cytokines. Int. Immunol. 13(5), 675-683 (2001). (Pubitemid 32427870)
48. Puig-Kroger A, Relloso M, Fernandez-Capetillo O et al.: Extracellular signal-regulated protein kinase signaling pathway negatively regulates the phenotypic and functional maturation of monocyte-derived human dendritic cells. Blood 98(7), 2175-2182 (2001).
49. Agrawal A, Dillon S, Denning TL, Pulendran B: Erk1-/- mice exhibit Th1 cell polarization and increased susceptibility to experimental autoimmune encephalomyelitis. J. Immunol. 176(10), 5788-5796 (2006).
50. Sato K, Nagayama H, Tadokoro K, Juji T, Takahashi TA: Extracellular signal-regulated kinase, stress-activated protein kinase/c-Jun N-terminal kinase, and p38MAPK are involved in IL-10-mediated selective repression of TNF-a-induced activation and maturation of human peripheral blood monocyte-derived dendritic cells. J. Immunol. 162(7), 3865-3872 (1999). (Pubitemid 29314764)
51. Ardeshna KM, Pizzey AR, Devereux S, Khwaja A: The PI3 kinase, p38 sap kinase, and NF-kB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood 96(3), 1039-1046 (2000). (Pubitemid 30616871)
52. Escors D, Lopes L, Lin R et al.: Targeting dendritic cell signaling to regulate the response to immunization. Blood 111(6), 3050-3061 (2008).
53. Dong C, Davis Rj, Flavell RA: MAP kinases in the immune response. Annu. Rev. Immunol. 20, 55-72 (2002). (Pubitemid 34293420)
54. Alberola-Ila J, Forbush KA, Seger R, Krebs EG, Perlmutter RM: Selective requirement for MAP kinase activation in thymocyte differentiation. Nature 373(6515), 620-623 (1995).
55. Stefanova I, Hemmer B, Vergelli M, Martin R, Biddison WE, Germain RN: TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat. Immunol. 4(3), 248-254 (2003). (Pubitemid 36322134)
56. Tan AH, Lam KP: Pharmacologic inhibition of MEK-ERK signaling enhances Th17 differentiation. J. Immunol. 184(4), 1849-1857 (2010).
57. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23(5), 1011-1027 (2005). (Pubitemid 46202320)
58. Forsythe JA, Jiang BH, Iyer NV et al.: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol. 16(9), 4604-4613 (1996). (Pubitemid 26272112)
59. Shchors K, Evan G: Tumor angiogenesis: cause or consequence of cancer? Cancer Res. 67(15), 7059-7061 (2007). (Pubitemid 47206529)
60. Tang N, Wang L, Esko J et al.: Loss of HIF-1a in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6(5), 485-495 (2004). (Pubitemid 39469984)
61. Ellis LM, Fidler IJ: Angiogenesis and metastasis. Eur. J. Cancer 32A(14), 2451-2460 (1996).
62. Gabrilovich D, Ishida T, Oyama T et al.: Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92(11), 4150-4166 (1998). (Pubitemid 28544331)
63. Gabrilovich DI, Chen HL, Girgis KR et al.: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2(10), 1096-1103 (1996). (Pubitemid 26338628)
64. Gabrilovich DI, Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9(3), 162-174 (2009).
65. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP: Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 5(10), 2963-2970 (1999). (Pubitemid 29493976)
66. Varney ML, Johansson SL, Singh RK: Tumour-associated macrophage infiltration, neovascularization and aggressiveness in malignant melanoma: role of monocyte chemotactic protein-1 and vascular endothelial growth factor-a. Melanoma Res. 15(5), 417-425 (2005). (Pubitemid 41558952)
67. Ueno T, Toi M, Saji H et al.: Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 6(8), 3282-3289 (2000). (Pubitemid 30637758)
68. Solinas G, Germano G, Mantovani A, Allavena P: Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 86(5), 1065-1073 (2009).
69. Paik S, Shak S, Tang G et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817-2826 (2004). (Pubitemid 40051905)
70. Ohm JE, Gabrilovich DI, Sempowski GD et al.: VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101(12), 4878-4886 (2003). (Pubitemid 36857749)
71. Li B, Lalani AS, Harding TC et al.: Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin. Cancer Res. 12(22), 6808-6816 (2006). (Pubitemid 44876851)
72. Huang Y, Chen X, Dikov Mm et al.: Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 110(2), 624-631 (2007). (Pubitemid 47105401)
73. Fricke I, Mirza N, Dupont J et al.: Vascular endothelial growth factor-TRAP overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin. Cancer Res. 13(16), 4840-4848 (2007). (Pubitemid 47298146)
74. Escudier B, Eisen T, Stadler WM et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007). (Pubitemid 46089673)
75. Llovet JM, Ricci S, Mazzaferro V et al.: Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378-390 (2008).
76. Motzer RJ, Hutson TE, Tomczak P et al.: Sunitinib versus interferon-a in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115-124 (2007). (Pubitemid 46089672)
77. Maemondo M, Inoue A, Kobayashi K et al.: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362(25), 2380-2388 (2010).
78. Hodi FS, Friedlander P, Corless CL et al.: Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol. 26(12), 2046-2051 (2008).
79. Lutzky J, Bauer J, Bastian BC: Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res. 21(4), 492-493 (2008). (Pubitemid 351990966)
80. Boissel N, Rousselot P, Raffoux E et al.: Imatinib mesylate minimally affects BCR-ABL+ and normal monocyte-derived dendritic cells but strongly inhibits T-cell expansion despite reciprocal dendritic cell-T cell activation. J. Leukoc. Biol. 79(4), 747-756 (2006). (Pubitemid 44835607)
81. Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S: Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104(4), 1094-1099 (2004). (Pubitemid 39038030)
82. Cwynarski K, Laylor R, Macchiarulo E et al.: Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 18(8), 1332-1339 (2004). (Pubitemid 39136740)
83. Seggewiss R, Lore K, Greiner E et al.: Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 105(6), 2473-2479 (2005). (Pubitemid 40387048)
84. Mumprecht S, Matter M, Pavelic V, Ochsenbein AF: Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood 108(10), 3406-3413 (2006).
85. Mattiuzzi GN, Cortes JE, Talpaz M et al.: Development of varicella-zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin. Cancer Res. 9(3), 976-980 (2003). (Pubitemid 36323700)
86. Gao H, Lee BN, Talpaz M et al.: Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia 19(11), 1905-1911 (2005). (Pubitemid 41553998)
87. Zipfel PA, Zhang W, Quiroz M, Pendergast AM: Requirement for ABL kinases in T cell receptor signaling. Curr. Biol. 14(14), 1222-1231 (2004). (Pubitemid 38991808)
88. Larmonier N, Janikashvili N, Lacasse CJ et al.: Imatinib mesylate inhibits CD4+ CD25+ regulatory T-cell activity and enhances active immunotherapy against BCR-ABL-tumors. J. Immunol. 181(10), 6955-6963 (2008).
89. Agosti V, Corbacioglu S, Ehlers I et al.: Critical role for KIT-mediated Src kinase but not PI 3-kinase signaling in pro T- and pro B-cell development. J. Exp. Med. 199(6), 867-878 (2004). (Pubitemid 38375206)
90. Chen CI, Maecker HT, Lee PP: Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood 111(11), 5342-5349 (2008).
91. Appel S, Boehmler AM, Grunebach F et al.: Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 103(2), 538-544 (2004). (Pubitemid 38140084)
92. Appel S, Rupf A, Weck Mm et al.: Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kB and Akt signaling pathways. Clin. Cancer Res. 11(5), 1928-1940 (2005). (Pubitemid 40471859)
93. Mohty M, Jourdan E, Mami NB et al.: Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. Blood 103(12), 4666-4668 (2004). (Pubitemid 38746000)
94. Taieb J, Maruyama K, Borg C, Terme M, Zitvogel L: Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. Blood 103(5), 1966-1967; author reply 1967 (2004). (Pubitemid 38269001)
95. Wang H, Cheng F, Cuenca A et al.: Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 105(3), 1135-1143 (2005). (Pubitemid 40170886)
96. Wehner R, Wendisch M, Schakel K et al.: Imatinib mesylate does not impair the immunogenicity of human myeloid blood dendritic cells. Leukemia 20(9), 1629-1632 (2006). (Pubitemid 44264112)
97. Borg C, Terme M, Taieb J et al.: Novel mode of action of c-KIT tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest. 114(3), 379-388 (2004). (Pubitemid 39071610)
98. Mignot G, Ullrich E, Bonmort M et al.: The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2. J. Immunol. 180(10), 6477-6483 (2008).
99. Smyth MJ: Imatinib mesylate - uncovering a fast track to adaptive immunity. N. Engl. J. Med. 354(21), 2282-2284 (2006).
100. Van Dongen M, Savage ND, Jordanova ES et al.: Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int. J. Cancer 127(4), 899-909 (2010).
101. Rini Bi: Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin. Cancer Res. 14(5), 1286-1290 (2008).
102. Carlomagno F, Anaganti S, Guida T et al.: Bay 43-9006 inhibition of oncogenic RET mutants. J. Natl Cancer Inst. 98(5), 326-334 (2006). (Pubitemid 43338212)
103. Wilhelm SM, Carter C, Tang L et al.: Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64(19), 7099-7109 (2004). (Pubitemid 39331023)
104. Hipp MM, Hilf N, Walter S et al.: Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111(12), 5610-5620 (2008).
105. Alfaro C, Suarez N, Gonzalez A et al.: Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br. J. Cancer 100(7), 1111-1119 (2009).
106. Molhoek KR, Mcskimming CC, Olson WC, Brautigan DL, Slingluff CL Jr: Apoptosis of CD4+CD25high T cells in response to sirolimus requires activation of T cell receptor and is modulated by IL-2. Cancer Immunol. Immunother. 58(6), 867-876 (2009).
107. Zhao W, Gu YH, Song R, Qu BQ, Xu Q: Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia 22(6), 1226-1233 (2008). (Pubitemid 351833791)
108. Houben R, Voigt H, Noelke C, Hofmeister V, Becker JC, Schrama D: MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib. Mol. Cancer Ther. 8(2), 433-440 (2009).
109. Motzer RJ, Rini BI, Bukowski RM et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295(21), 2516-2524 (2006). (Pubitemid 43854967)
110. Finke JH, Rini B, Ireland J et al.: Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin. Cancer Res. 14(20), 6674-6682 (2008).
111. Ko JS, Zea AH, Rini BI et al.: Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15(6), 2148-2157 (2009).
112. Ko JS, Rayman P, Ireland J et al.: Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 70(9), 3526-3536 (2010).
113. Van Cruijsen H, Van Der Veldt AA, Vroling L et al.: Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin. Cancer Res. 14(18), 5884-5892 (2008).
114. Ozao-Choy J, Ma G, Kao J et al.: The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 69(6), 2514-2522 (2009).
115. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H: Sunitinib inhibition of STAT3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 69(6), 2506-2513 (2009).
116. Sinai P, Berg RE, Haynie JM, Egorin MJ, Ilaria RL Jr, Forman J: Imatinib mesylate inhibits antigen-specific memory CD8 T-cell responses in vivo. J. Immunol. 178(4), 2028-2037 (2007). (Pubitemid 46233399)
117. Chapman P Pi, Sosman J et al.: Early efficacy signal demonstrated in advanced melanoma in a Phase I trial of the oncogenic BRAF-selective inhibitor PLX4032. Eur. J. Cancer 7(3), 5 (2009).
118. Flaherty K, Puzanov I, Sosman J et al.: Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J. Clin. Oncol. 27(Suppl. 15), Abstract 9000 (2009).
119. Seliger B, Massa C, Rini B, Ko J, Finke J: Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors. Trends Mol. Med. 16(4), 184-192 (2010).
120. Boni A, Cogdill AP, Dang P et al.: Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70(13), 5213-5219 (2010).